Update on Intravitreal Injectable Drugs and Dry AMD Treatments
Experts InSight
00:00
The Impact of Biosimilars and FDA Approved Versions of Drugs on Costs and Access
The chapter discusses the concerns about the potential offset of cost savings from biosimilar adoption by the higher cost of an FDA approved version of a drug. It also explores the effects on copays, access, and intended outcomes, highlighting the complexity and potential increase in costs as more drugs and indications become available.
Transcript
Play full episode
